Cost-effective use of liposomal amphotericin B

Clinical and Laboratory Haematology

Volumn 24, Issue 5, 2002, Pages 317-319

  O'Connell, B ^a,b   Craig, J I O ^a   Marcus, R E ^a   Ludlam, H ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; LETTER; LUNG ASPERGILLOSIS; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REDUCTION; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; COST-BENEFIT ANALYSIS; DRUG COSTS; ENGLAND; HUMANS; LIPOSOMES; LIVER TRANSPLANTATION; LUNG DISEASES, FUNGAL; MEDICAL AUDIT; MYCOSES; NEUTROPENIA; ORGANIZATIONAL POLICY; POSTOPERATIVE COMPLICATIONS; SINUSITIS; TREATMENT OUTCOME;

EID: 0036399601     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.2002.00468.x     Document Type: Letter

References (7)

1. Ascioglu S., De Pauw B., Bennett J.E., Bille J., Crokaert F., Denning D.W., Donnelly P., Edwards J.E., Erjavec Z., Fiere D., Lortholary O., Maertens J., Meis J.F.G.M., Patterson T., Rex J.H., Ritter J., Selleslag D., Shah P.M., Stevens D.A. & Walsh T.J. (1999) Analysis of Definitions Used In Clinical Research on Invasive Fungal Infections: Consensus Proposal for New, Standardized Definitions. Poster presented at 39th ICAAC in San Francisco. Poster number 1639 in session 159.J - Management of Fungal Infections in Humans.
2. Cagnoni P., Walsh T.J., Prendergast M., Bodensteiner D., Hiemenz S., Greenberg R.N., Arndt C.A.S., Schuster M., Seibel N., Yeldandi V. & Tong K.B. (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Clinical Oncology 18, 2476-2483.
3. Denning D.W. (1996) Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23, 608-615.
4. Leenders A.C., Daenen S., Jansen R.L.H., Hop W.C.J., Lowenberg B., Wijermans P.W., Cornelissen J., Herbrecht R., van der Lelie H., Hoogsteden H.C., Verburgh H.A. & de Marie S. (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. British Journal of Haematology 103, 205-212.
5. Prentice H.G., Hann I.M., Herbrecht R., Aoun M., Rualoy S., Catovsky D., Pinkerton C.R., Schey S.A., Jacobs F., Oakhill A., Stevens R.F., Darbyshire P.J. & Gibson B.E.S. (1997) A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology 98, 711-718.
6. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., Bennett J.E., Walsh T.J., Patterson T.F. & Pankey G.A. (2000) Practice Guidelines for Diseases Caused by Aspergillus. Clinical Infectious Diseases 30, 696-709.
7. Wingard J.R., Kublis P., Lee L., Yee G., White M., Walshe L., Bowden R., Anaissie E., Hiemenz J. & Lister J. (1999) Clinical significance of nephrotoxicity inpatients treated with amphotericin B for suspected or proven aspergillosis. Ciinical Infectious Diseases 29, 1402-1407